These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24811082)

  • 1. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
    Gratas C; Séry Q; Rabé M; Oliver L; Vallette FM
    Oncotarget; 2014 May; 5(9):2428-35. PubMed ID: 24811082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
    Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
    Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
    Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
    Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
    Li RY; Chen LC; Zhang HY; Du WZ; Feng Y; Wang HB; Wen JQ; Liu X; Li XF; Sun Y; Yang DB; Jiang T; Li YL; Jiang CL
    CNS Neurosci Ther; 2013 Jul; 19(7):477-83. PubMed ID: 23551751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
    Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK
    Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
    Shi L; Chen J; Yang J; Pan T; Zhang S; Wang Z
    Brain Res; 2010 Sep; 1352():255-64. PubMed ID: 20633539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
    Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C
    Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
    Séry Q; Rabé M; Oliver L; Vallette FM; Gratas C
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1377-1383. PubMed ID: 28970067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
    Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW
    Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
    Zhou Y; Wang HD; Zhu L; Cong ZX; Li N; Ji XJ; Pan H; Wang JW; Li WC
    Oncol Rep; 2013 Jan; 29(1):394-400. PubMed ID: 23128449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
    Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
    J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of ILK promotes temozolomide resistance in glioma cells.
    Liang F; Wang B; Bao L; Zhao YS; Zhang SM; Zhang SQ
    Mol Med Rep; 2017 Mar; 15(3):1297-1304. PubMed ID: 28138714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
    Han J; Chen Q
    Int J Clin Exp Pathol; 2015; 8(10):12698-707. PubMed ID: 26722459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
    Ma J; Murphy M; O'Dwyer PJ; Berman E; Reed K; Gallo JM
    Biochem Pharmacol; 2002 Apr; 63(7):1219-28. PubMed ID: 11960598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
    Zhu D; Tu M; Zeng B; Cai L; Zheng W; Su Z; Yu Z
    Cancer Med; 2017 Feb; 6(2):452-462. PubMed ID: 28064447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.